Brief: Cantargia Clinical Data On Nadunolimab In Triple-Negative Breast Cancer Shows Combination Therapy Well Tolerated

Cantargia AB

16/10/2023 06:42

Oct 16 (Reuters) - Cantargia AB  CANTA.ST :
    * SAID CLINICAL DATA FROM PHASE IB TRIFOUR TRIAL,
INVESTIGATING
THE IL1RAP-BINDING ANTIBODY NADUNOLIMAB (CAN04) IN
TRIPLE-NEGATIVE BREAST CANCER (TNBC), SHOWS THAT COMBINATION
THERAPY WAS WELL TOLERATED 
    * PRELIMINARY RESPONSE RATE OF 50% IN 12 PATIENTS EVALUABLE
FOR
EFFICACY

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nNDLb19YBM
 Further company coverage:  CANTA.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))